Mandate

Vinge advises ITAB in connection with a recapitalisation of SEK 868 million

February 11, 2021 Capital Markets and Public M&A

The recapitalisation is carried out to strengthen ITAB’s capital structure to reduce the financial leverage of the group, to invest in the One ITAB transformation plan and to provide sufficient headroom to the business given the Covid-19 situation.

The recapitalisation entails that the equity is strengthened by approx. SEK 868 million by a rights issue of SEK 768 million and a set-off issue of SEK 100 million and entails further that Aeternum Capital becomes ITAB’s largest shareholder with a holding of approx. 25 percent of the shares. First day of trading in the new class B shares issued as a result of the recapitalisation is estimated to be 22 March 2021.

ITAB sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The offer includes custom-made fitting concepts, innovative solutions for the checkout area, professional lighting systems and interactive products. Customers include major retail chains throughout most of Europe. ITAB’s class B shares are listed on Nasdaq Stockholm.

Vinge’s team mainly consisted of Charlotte Levin, Rikard Lindahl, Annika Nyberg Ekenberg, Clara Sohlberg, Mikaela Falkner, Henrik Wastenson and David Bokliden.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025